Category: 86393-32-0

On January 3, 2008, Tornero Montano, Jose Ruben; Quintana Hau, Juan De Dios; Baiza Duran, Leopoldo Martin; Rodriguez Franco, Norma Patricia; Gonzalez, Jaime R.; Jimenez Bayardo, Arturo published a patent.Formula: C17H21ClFN3O4 The title of the patent was An ophthalmic formulation in suspension of loteprednol etabonate and ciprofloxacin hydrochloride. And the patent contained the following:

The invention concerns a topically applied ophthalmic formulation in suspension which contains loteprednol etabonate and ciprofloxacin hydrochloride. Moreover, said formulation contains a polymer as a thickening agent which is derived from the acrylic acid known generically as Carbopol, a nonionic surfactant, an ionic tonicity agent and a nonionic tonicity agent, which are physico-chem. compatible, stable and appropriately dissolved in the suspension. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Formula: C17H21ClFN3O4

The Article related to loteprednol etabonate ciprofloxacin ophthalmic formulation, Pharmaceuticals: Formulation and Compounding and other aspects.Formula: C17H21ClFN3O4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On December 11, 2003, Sherman, Bernard Charles published a patent.Reference of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate The title of the patent was Tablets comprising ciprofloxacin hydrochloride. And the patent contained the following:

A pharmaceutical tablet comprising over 80% by weight ciprofloxacin hydrochloride monohydrate is disclosed. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Reference of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

The Article related to ciprofloxacin hydrochloride monohydrate tablet formulation, Pharmaceuticals: Formulation and Compounding and other aspects.Reference of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On May 10, 2001, Kabra, Bhagwati P. published a patent.Category: piperazines The title of the patent was Pharmaceutical compositions containing a fluoroquinolone antibiotic drug and xanthan gum. And the patent contained the following:

Pharmaceutical compositions containing a fluoroquinolone antibiotic drug, xanthan gum and a water-soluble calcium salt in an amount sufficient to make the fluoroquinolone antibiotic drug and xanthan gum compatible are disclosed. A pharmaceutical composition contained ciprofloxacin.HCl 0.35, xanthan gum 0.6, sodium sulfate 1.5, disodium edetate 0.05, BDAB 0.012, NaOH/HCl q.s. pH = 4.5, and water q.s. 100%. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Category: piperazines

The Article related to pharmaceutical fluoroquinolone antibiotic drug xanthan gum, Pharmaceuticals: Formulation and Compounding and other aspects.Category: piperazines

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On April 30, 1987, Lammens, Robert Frank; Mahler, Hans Friedrich; Serno, Peter published a patent.Electric Literature of 86393-32-0 The title of the patent was Infusion solution of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-quinoline-3-carboxylic acid (ciprofloxacin), especially for antibacterial use. And the patent contained the following:

Aqueous infusion solutions for especially antibacterial use contain ciprofloxacin 0.015-0.5 g/100 mL of a physiol. acceptable acid as stabilizer, with optional adjuvants. An infusion solution contained ciprofloxacin 90, lactic acid (20% g/g) 144.3, HCl 1.5, NaCl 5.4g, and water to 600 mL; its pH was ∼4.3 and osmolarity ∼0.29 osm/kg. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Electric Literature of 86393-32-0

The Article related to antibacterial infusion solution ciprofloxacin acid, Pharmaceuticals: Formulation and Compounding and other aspects.Electric Literature of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Hashem, F. M.; Sakran, W. S.; Shaker, D. S. published an article in 2003, the title of the article was Ocular bioavailability of ciprofloxacin hydrochloride from certain ophthalmic preparations.Application of 86393-32-0 And the article contains the following content:

The bioavailability of ciprofloxacin hydrochloride (CPX-HCl) in eye tissues and aqueous humor of rabbits was studied. The selected ophthalmic preparations were ophthalmic solution (eye drops) containing hydroxy Pr Me cellulose (HPMC), ophthalmic gels prepared with HPMC or Me cellulose (MC) or sodium alginate. Ocular inserts were prepared from HPMC, or MC or Eudragit RS. The time for peak concentration (tmax) of the drug in the eye tissues and aqueous humor was attained after one hour from the ophthalmic solution, while it was two hours in case of ophthalmic gels irresp. to polymer type. Ocular inserts prepared from HPMC or MC also showed peak concentration time of two hours after application in the rabbit’s eyes. However, the tmax was reached after three hours from Eudragit RS ocular inserts. In all tested ophthalmic formulations. CPX-HCL was available in conjunctiva in a higher concentration than in the cornea, while iris-ciliary body and aqueous humor showed less drug concentration at all time intervals. The corneal drug bioavailability represented by the area under the curve (AUC)0-5 was greatly improved after the application of ocular inserts than other forms (solution or gel). Thus Eudragit RS ocular inserts showed the highest level of the drug bioavailability in eye tissues and aqueous humor due to prolonged retention time, whereas ophthalmic solution was rapidly uptaken and eliminated by tears from eye tissues. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Application of 86393-32-0

The Article related to ciprofloxacin ophthalmic ocular bioavailability, Pharmaceuticals: Formulation and Compounding and other aspects.Application of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On May 1, 2003, Gusler, Gloria; Berner, Bret; Chau, Mei; Padua, Aimee published a patent.Safety of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate The title of the patent was Optimal polymer mixtures for gastric retentive tablets. And the patent contained the following:

Unit dosage form tablets for the delivery of pharmaceuticals are formed of the pharmaceutical dispersed in a solid unitary matrix that is formed of a combination of PEG and hydroxypropyl Me cellulose. The combination offers unique benefits in terms of release rate control and reproducibility while allowing both swelling of the tablet to effect gastric retention and gradual disintegration of the tablet to clear the tablet from the gastrointestinal tract after release of the drug has occurred. Thus, tablets contained gabapentin 60.0,,PEG 24.3, HPMC 14.7, and Mg stearate 1.0%. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Safety of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

The Article related to polymer mixture gastric retentive tablet, Pharmaceuticals: Formulation and Compounding and other aspects.Safety of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On February 27, 2008, Amirov, N. K.; Egorova, S. N.; Akhmetova, T. A.; Fedorov, A. A.; Galiullina, T. N.; Karipova, R. M.; Stepanova, N. V. published a patent.Recommanded Product: 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate The title of the patent was Composition and method for preparing ciprofloxacin ophthalmic ointment. And the patent contained the following:

The invention proposes an ophthalmic ointment containing ciprofloxacin hydrochloride monohydrate equivalent to the concentration 0.1-0.9% as a free base, a preserving agent, for example nipagin or nipasol, and a sterile base consisting of vaseline melt of sort “”for ophthalmic ointments”” and anhydrous lanolin. The ophthalmic ointment is prepared by melting vaseline and anhydrous lanolin and step-by-step mixing milled ciprofloxacin hydrochloride and the preserving agent with sterile base. The invention provides producing a sterile and stable ciprofloxacin-containing ophthalmic ointment used for local treatment of eye inflammatory diseases and of bacterial etiol. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Recommanded Product: 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

The Article related to eye ointment ciprofloxacin formulation, Pharmaceuticals: Formulation and Compounding and other aspects.Recommanded Product: 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On February 22, 2001, Fekete, Pal; Fellner, Gyorgy, Mrs.; Gora, Laszlo, Mrs.; Jambor, Istvan, Mrs.; Feikus, Szilvia; Palfi, Zoltan, Mrs.; Zsigmond, Zsolt published a patent.Recommanded Product: 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate The title of the patent was Ciprofloxacin-containing pharmaceutical composition and process for the preparation thereof. And the patent contained the following:

The invention relates to an immediate-release pharmaceutical composition containing ciprofloxacin, a binder, disintegrating agent and optionally further pharmaceutical auxiliary agents. The composition comprises 60-80 % of ciprofloxacin (in the form of ciprofloxacin hydrochloride monohydrate), 2-10 % of maltodextrin, 5-15 % of a disintegrating agent of carboxymethyl starch type, 3-6 % of silica, 1-3 % of a lubricant and optional 2-6 % of a film-coating layer for film-coated tablets. A tablet contained ciprofloxacin hydrochloride monohydrate 582, Na CM starch 82, maltodextrin 40, silica 40, Mg stearate 6, and Opadry Y-1-7000 16 mg. The tablet was dissolved in the amounts of 94.3, 95.4, and 98.5 % in 5, 15, and 30 min, resp. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Recommanded Product: 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

The Article related to immediate release tablet ciprofloxacin, Pharmaceuticals: Formulation and Compounding and other aspects.Recommanded Product: 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On December 31, 2008, Pastini, Ana C.; Faour, Joaquina; Vergez, Juan A.; Ricci, Marcelo A.; Fischbein, Gustavo A. published a patent.Recommanded Product: 86393-32-0 The title of the patent was A rupturing controlled release device comprising a subcoat. And the patent contained the following:

The present invention provides a simple and improved rupturing controlled release device that is capable of providing a controlled release of active agent contained in the core first through a preformed passageway and then through an in situ formed second passageway into an environment of use in a standardized release profile manner. The rupturing controlled release device comprises a core comprising at least one drug and at least one osmopolymer, a semipermeable membrane enclosing the core and having at least one preformed passageway there through, wherein the semipermeable membrane ruptures during use to form a second passageway in the semipermeable membrane at a location spaced away from the preformed passageway, and a release-controlling subcoat between the core and the semipermeable membrane. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Recommanded Product: 86393-32-0

The Article related to controlled release delivery rupturing, Pharmaceuticals: Formulation and Compounding and other aspects.Recommanded Product: 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On March 28, 2002, Singh, Onkar N.; Bhagat, Haresh G.; Kabra, Bhagwati P. published a patent.Category: piperazines The title of the patent was Topical composition comprising ciprofloxacin and hydrocortisone. And the patent contained the following:

This invention is directed toward a topical composition comprising ciprofloxacin and hydrocortisone, where the composition contains a specific grade of poly(vinyl alc.) as a viscosity augmenter. The specified grade of polyvinyl alc. is 85-90% hydrolyzed poly(vinyl alc.). Thus, a composition contained ciprofloxacin-HCl monohydrate 0.35, micronized hydrocortisone 1.9, benzyl alc. 0.9, NaCl 0.9, sodium acetate trihydrate 0.68, acetic acid 0.255, Phospholipon 90H 0.15, Polysorbate-20 0.10, NaOH and/or HCl to pH 4.7, and water to 100%. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Category: piperazines

The Article related to topical ciprofloxacin hydrocortisone, Pharmaceuticals: Formulation and Compounding and other aspects.Category: piperazines

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics